PER 2.50% 8.2¢ percheron therapeutics limited

Chart, page-4335

  1. 4,345 Posts.
    lightbulb Created with Sketch. 2030
    Yes a CR would be dilutive. But look at the reward it would bring market cap wise if the trial goes to plan. This more than makes up for any dilution now. And this is only considering DMD.

    This trial, when done and if sucessful, opens a non diluting funding stream into all the other indications.

    So there are plenty of positives for both CR and partnership.

    Company making times at the moment.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.2¢
Change
0.002(2.50%)
Mkt cap ! $73.92M
Open High Low Value Volume
8.1¢ 8.5¢ 8.1¢ $145.4K 1.739M

Buyers (Bids)

No. Vol. Price($)
1 69272 8.2¢
 

Sellers (Offers)

Price($) Vol. No.
8.4¢ 71037 1
View Market Depth
Last trade - 16.10pm 15/08/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.